The estimated Net Worth of Ted W Love is at least $65.9 Milion dollars as of 27 September 2022. Ted Love owns over 18,291 units of Global Blood Therapeutics stock worth over $39,472,020 and over the last 16 years he sold GBT stock worth over $16,350,583. In addition, he makes $10,097,200 as President, Chief Executive Officer a Director at Global Blood Therapeutics.
Ted has made over 21 trades of the Global Blood Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 18,291 units of GBT stock worth $299,972 on 27 September 2022.
The largest trade he's ever made was exercising 87,500 units of Global Blood Therapeutics stock on 13 December 2019 worth over $5,992,875. On average, Ted trades about 8,783 units every 38 days since 2009. As of 27 September 2022 he still owns at least 576,318 units of Global Blood Therapeutics stock.
You can see the complete history of Ted Love stock trades at the bottom of the page.
Dr. Ted Wendell Love M.D. serves as President, Chief Executive Officer, Director of the Company. He has served as our Chief Executive Officer and President since June 2014, and as a member of our Board of Directors since September 2013. From February 2010 to August 2012, Dr. Love served as executive vice president, research and development and technical operations of Onyx Pharmaceuticals, Inc. Prior to that, from 2001 to January 2009, he served as president, chief executive officer and chairman of Nuvelo, Inc., and previously served as senior vice president, development of Theravance, Inc., from 1998 to 2001. Previously, he spent six years at Genentech, Inc., where he held a number of senior management positions in medical affairs and product development and served as chairman of Genentech’s Product Development Committee. Dr. Love currently serves on the board of directors of Amicus Therapeutics, Inc., a biotechnology company, and Portola Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Love also currently serves on the board of directors of the Biotechnology Innovation Organization (BIO), a non-profit biotechnology trade organization. Dr. Love holds a B.A. from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and fellowship in cardiology at the Massachusetts General Hospital. Dr. Love’s qualifications to serve on our Board of Directors include his role as our principal executive officer and more than 20 years of broad leadership and management experience in the pharmaceutical industry.
As the President, Chief Executive Officer a Director of Global Blood Therapeutics, the total compensation of Ted Love at Global Blood Therapeutics is $10,097,200. There are no executives at Global Blood Therapeutics getting paid more.
Ted Love is 61, he's been the President, Chief Executive Officer a Director of Global Blood Therapeutics since 2014. There are 9 older and 12 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.
Ted's mailing address filed with the SEC is C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK, NY, 10022.
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third... a Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Global Blood Therapeutics executives and other stock owners filed with the SEC include: